Absence of routine molecular testing and prevalence of HIV-2 infection in regions hardest-hit by HIV infection

Journal of Infection in Developing Countries

Volumn 6, Issue 12, 2012, Pages 854-859

  Forbi, Joseph C ^a,b   Esona, Mathew D ^a   Iperepolu, Hellen O ^a   Adoga, Moses P ^a,c   Agwale, Simon M ^a,b  

^a Clinical Virology Laboratory   (Nigeria)

^b Frederick Innovative Technology Center   (United States)

^c NASARAWA STATE UNIVERSITY   (Nigeria)

Author keywords

False negative diagnosis; Fsws; HIV 2; Nigeria

Indexed keywords

ADULT; ARTICLE; CROSS-SECTIONAL STUDY; FEMALE; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; MAJOR CLINICAL STUDY; MIXED INFECTION; NIGERIA; NUCLEIC ACID ANALYSIS; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; PREVALENCE; RISK; RNA EXTRACTION; SERODIAGNOSIS; VIRUS LOAD;

EID: 84876273941     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.2298     Document Type: Article

References (24)

1. United Nations General Assembly Special Session on HIV and AIDS (UNGASS) (2010) UNGASS Country progress report HIV/AIDS: Nigeria. Available: http://www.unaids.org/en/dataanalysis/monitoringcountryprogress/2010progressreportssubmittedbycountries/nigeria_2010_country_progress_report_en.pdf.Accessed 26 July 2011.
2. Odaibo GN, Olaleye OD, Tomori O (1998) Human immunodeficiency virus types 1 and 2 infection in some rural areas of Nigeria. Rom J Virol 49: 89-95.
3. Zeh C, Pieniazek D, Agwale SM, Robbins KE, Odama L, Sani-Gwarzo N, Gboun MS, Inyang US, Folks TM, Wambebe C, Kalish ML (2005) Nigerian HIV type 2 subtype A and B from heterotypic HIV type 1 and HIV type 2 or monotypic HIV type 2 infections. AIDS Res Hum Retroviruses 21: 17-27.
4. Guyader M, Emerman M, Sonigo P, Clavel F, Montagnier L, Alizon M (1987) Genome organization and transactivation of the human immunodeficiency virus type 2. Nature 326: 662-669.
5. UNAIDS (2007) AIDS epidemic update. Available: http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf.Accessed 20 July 2011.
6. De Cock KM, Adjorlolo G, Ekpini E, Sibailly T, Kouadio J, Maran M, Brattegaard K, Vetter KM, Doorly R, Gayle HD (1993) Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic. JAMA 270: 2083-2086.
7. Reeves JD, Doms RW (2002) Human immunodeficiency virus type 2. J Gen Virol 83: 1253-1265.
8. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W (2004) Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 9: 57-65.
9. Odaibo GN, Taiwo A, Aken'Ova YA, Olaleye DO (2008) Detection of HIV antigen and cDNA among antibody-negative blood samples in Nigeria. Trans R Soc Trop Med Hyg 102: 284-287.
10. Kostman JR (2002) Testing for the virus. In: Buckley, Michael R. and Stephen J. Gluckman. HIV Infection in Primary Care. Philadelphia: W.B. Saunders Company.
11. Forbi JC, Entonu PE, Mwangi LO, Agwale SM (2011) Estimates of human immunodeficiency virus incidence among female sex workers in north central Nigeria: implications for HIV clinical trials. Trans R Soc Trop Med Hyg 105: 655-660.
12. Weusten JJ, Carpay WM, Oosterlaken TA, van Zuijlen MC, van de Wiel PA (2002) Principles of quantitation of viral loads using nucleic acid sequence-based amplification in combination with homogeneous detection using molecular beacons. Nucleic Acids Res 30: e26.
13. Stevens W, Wiggill T, Horsfield P, Coetzee L, Scott LE (2005) Evaluation of the NucliSens EasyQ assay in HIV-1-infected individuals in South Africa. J Virol Methods 124: 105-110.
14. Parry JV, Mahoney A, Mortimer PP (1993) Are seroepidemiological surveys for human immunodeficiency virus infection based on tests on pools of serum specimens accurate and cost-effective? Clin Diagn Virol 1: 167-178.
15. Ekweozor CC, Olaleye OD, Tomori O, Saliu I, Essien EM, Bakare RA, Oni AA, Oyewo OO, Okesola AO, Onyemenem TN (1995) Clinico-epidemiological patterns of HIV infection in STD patients in Ibadan. Afr J Med Med Sci 24: 321-327.
16. Shokunbi WA, Saliu I, Essien EM (1995) Incidence of dual presence of antibodies to HIV1 and HIV2 in seropositive cases seen in Ibadan, Nigeria. Afr J Med Med Sci 24: 249-253.
17. Dada AJ, Oyewole F, Onofowokan R, Nasidi A, Harris B, Levin A, Diamondstone L, Quinn TC, Blattner WA (1993) Demographic characteristics of retroviral infections (HIV-1, HIV-2, and HTLV-I) among female professional sex workers in Lagos, Nigeria. J Acquir Immune Defic Syndr 6: 1358-1363.
18. Esu-Williams E, Mulanga-Kabeya C, Takena H, Zwandor A, Aminu K, Adamu I, Yetunde O, Akinsete I, Patrel D, Peeters M, Delaporte E (1997) Seroprevalence of HIV-1, HIV-2, and HIV-1 group O in Nigeria: evidence for a growing increase of HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 16: 204-210.
19. Olaleye OD, Bernstein L, Ekweozor CC, Sheng Z, Omilabu SA, Li XY, Sullivan-Halley J, Rasheed S (1993) Prevalence of human immunodeficiency virus types 1 and 2 infections in Nigeria. J Infect Dis 167: 710-714.
20. Falk BW, Tian T, Yeh HH (1999) Luteovirus-associated viruses and subviral RNAs. Curr Top Microbiol Immunol 239: 159-175.
21. Scuracchio PS, Poli MC, Lemos MM, Oliveira Filho AG, Salles NA, Chamone DA, Magri M, Cavalcante NJ, Collela R (2007)Detection of HIV-1 infection in blood donors during the immunological window period using the nucleic acid-amplification technology. Transfus Med 17: 200-204.
22. Church D, Gregson D, Lloyd T, Klein M, Beckthold B, Laupland K, Gill MJ (2011) Comparison of the RealTime HIV-1, COBAS TaqMan 48 v1.0, Easy Q v1.2, and Versant v3.0 assays for determination of HIV-1 viral loads in a cohort of Canadian patients with diverse HIV subtype infections. J Clin Microbiol 49: 118-124.
23. Agwale SM, Forbi JC, Notka F, Wrin T, Wild J, Wagner R, Wolf H (2011) Broad Antibody Mediated Cross-Neutralization and Preclinical Immunogenicity of New Codon-Optimized HIV-1 Clade CRF02_AG and G Primary Isolates. PLoS One 6: e23233.
24. Basavaraju SV, Mwangi J, Nyamongo J, Zeh C, Kimani D, Shiraishi RW, Madoda R, Okonji JA, Sugut W, Ongwae S, Pitman JP, Marum LH (2010) Reduced risk of transfusion-transmitted HIV in Kenya through centrally co-ordinated blood centres, stringent donor selection and effective p24 antigen-HIV antibody screening. Vox Sang 99: 212-219.